A Phase 3 interventional study of Ustekinumab in Crohn Disease, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.
Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 17th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 18th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–70
By country, each count listing its studies:
Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 131 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW has 4 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing ustekinumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT06520397Sixth Affiliated Hospital, Sun Yat-sen UniversityEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | 2026-12-31 |
| NCT07303686McGill University Health Centre/Research Institute of the McGill University Health CentreDe-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing ustekinumab in Crohn Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to assess the long-term efficacy and safety of a ustekinumab 90mg subcutaneous (SC) every 4 weeks (Q4w) regimen in patients with Crohn's disease previously enrolled in the REScUE study (NCT04245215) because of secondary loss of response to a ustekinumab 90mg SC every 8 weeks (Q8w) regimen.
The study is a prospective, open-label study only enrolling patients that were previously included in the REScUE study (n=max. 108; NCT04245215) and that terminated that study at week 48. Patients will undergo most necessary examinations, including endoscopy, as part of the Week 48 visit of the REScUE study and those should therefore not be repeated as part of Week 0 visit of the REScUE-OLE study (W0 REScUE-OLE = W48 REScUE). The FACIT-Fatigue scale and the additional laboratory evaluations (serum creatinine, ALT, AST and conjugated bilirubin) are the only examinations that are not foreseen at the end of the REScUE study at week 48. During the 4-week period following the start of REScUE-OLE (= end of REScuE at Week 48), collection and monitoring of the patient's data within the REScUE study will first be finalized, after which unblinding takes place. Depending on the final outcome and treatment of the patient in REScUE ("Q8w responders", "Q8w non-responders", "Q4w responders"), the OLE treatment regimen will be decided as follows:
Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are "Q8w responders" at the end of REScUE, defined by the following criteria:
Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are "Q4w responders" at the end of REScUE, defined by the following criteria:
The consecutive CD treatment after REScUE-OLE cessation is at the discretion of the treating physician.
During the REScUE-OLE study, patients will have on-site, scheduled visits at 5 different timepoints. At each of these visits, the following study procedures will take place: registration of current (CD and non-CD) treatment, assessments of (serious) adverse events, disease activity assessment (PRO-2), physical examination, weight assessment, assessment of vital signs (blood pressure and pulse), laboratory evaluation (including CRP, haemoglobin, thrombocytes, serum albumin, serum creatinine, ALT, AST, conjugated bilirubin, and FC), patient diary review and instruction, and administration of commercially available ustekinumab 90 mg SC. At week 56 and at the end of the study at week 112, these study procedures will be complemented with pharmacokinetic sampling, an ileocolonoscopy and a monitoring of quality-of-life, work and productivity impairment and fatigue, using dedicated questionnaires. For all visits, a window of maximum 7 days is authorized. In between on-site visits, the administration of the medication is allowed off-site, following the schedule of the OLE treatment arm in which they are allocated. This can either be done by self-administration, for patients who have been trained to self-administer, or by a qualified medical professional.
Steroid use at the start and during the study is possible, but a strict tapering regimen is mandatory. Dose-escalation or (re-)initiation of steroids is allowed for a maximum of two times during the study period, with at least 6 months between the first and the second steroid dose-escalation/(re-)initiation. Patients treated with ustekinumab 90 mg SC Q8w will be able to cross-over to a ustekinumab 90 mg SC Q4w regimen if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE. Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q4w will stop the REScUE-OLE study and discontinue ustekinumab within the REScUE-OLE study, if they meet the criteria of CD worsening at two different timepoints (separated by at least 4 weeks) beyond week 12 after initiation of this OLE treatment regimen.
Primary endpoint of the REScUE-OLE study (sustained steroid-free clinical remission) will be assessed at week 112.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm during REScUE that did not reach the following criteria at the end of REScUE at week 48:
Patients with any of the following laboratory tests at W0 of the REScUE-OLE study :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are "Q8w responders" at the end of REScUE Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q8w will be able to cross-over to a OLE treatment regimen of ustekinumab 90 mg SC Q4w if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE
Drug: Ustekinumab
Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w ("Cross-over") if they are "Q8w non-responders" at the end of REScUE OR Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are "Q4w responders" at the end of REScUE
Drug: Ustekinumab
dose escalation from every 8 weeks to every 4 weeks only in arm 2
Also known as: dose escalation only in arm 2
Proportion of patients in both treatment arms in steroid-free clinical remission
Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at both week 56 and week 112 of the study (sustained steroid-free clinical remission).
Time frame: Week 56
Proportion of patients in both treatment arms in steroid-free clinical remission
Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at both week 56 and week 112 of the study (sustained steroid-free clinical remission).
Time frame: Week 112
Incidence and severity of adverse events in both treatment arms.
Time frame: week 112
Time to CD worsening in both treatment arms
Time frame: week 112
Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP <=1 and average SF <=3 without any steroid use in the previous 28 days) at week 56 of the study.
Time frame: Week 56
Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP <=1 and average SF <=3 without any steroid use in the previous 28 days) at week 112 of the study.
Time frame: Week 112
Proportion of patients previously enrolled to UST 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached steroid-free clinical remission at week 112.
Proportion of patients previously enrolled to the ustekinumab (UST) 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at week 112.
Time frame: Week 112
Proportion of patients in both treatment arms in clinical remission (PRO-2 remission: average AP <=1 and average SF <=3) at week 56 of the study (sustained clinical remission).
Time frame: Week 56
Proportion of patients in both treatment arms in clinical remission (PRO-2 remission: average AP <=1 and average SF <=3) at week 56 of the study.
Time frame: Week 112
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached clinical remission at week 112.
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3) at week 112.
Time frame: Week 112
Proportion of patients in both treatment arms with biomarker remission (CRP <5 mg/L and FC <=250 ug/g) at week 56 of the study.
Time frame: Week 56
Proportion of patients in both treatment arms with biomarker remission (CRP <5 mg/L and FC <=250 ug/g) at week 112 of the study.
Time frame: Week 112
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached biomarker remission at week 112.
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached biomarker remission (CRP \<5 mg/L and FC \<=250 ug/g) at week 112.
Time frame: Week 112
Proportion of patients in both treatment arms in endoscopic remission (total SES-CD <5) at week 56 of the study.
Time frame: Week 56
Proportion of patients in both treatment arms in endoscopic remission (total SES-CD <5) at week 112 of the study
Time frame: Week 112
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached endoscopic remission (at week 112.
Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached endoscopic remission (total SES-CD \<5) at week 112.
Time frame: Week 112
Proportion of patients in both treatment arms in complete endoscopic remission (total SES-CD <3) at week 56 of the study.
Time frame: Week 56
Proportion of patients in both treatment arms in complete endoscopic remission (total SES-CD <3) at week 112 of the study.
Time frame: Week 112
Proportion of patients previously enrolled to UST 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached complete endoscopic remission at week 112.
Proportion of patients previously enrolled to the ustekinumab (UST) 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached complete endoscopic remission (total SES-CD \<3) at week 112.
Time frame: Week 112
Pharmacokinetic evaluation
Drug levels in serum
Time frame: between baseline and week 112
Time until ustekinumab discontinuation (treatment persistence).
Time frame: between baseline and week 112
Improvements in quality-of-life based on 36-Item Short Form Survey Instrument (SF-36)
Improvements in quality-of-life based on 36-Item Short Form Survey Instrument (SF-36)
Time frame: between baseline and week 112
Fatigue as evaluated by the FACIT fatigue scale (functional assessment of chronic illness therapy-fatigue)
Fatigue as evaluated by the FACIT fatigue scale (functional assessment of chronic illness therapy-fatigue): a 4 point scale, with 0 = not fatigue and 4= very much fatigue
Time frame: between baseline and week 112
Work productivity as evaluated by the WPAI (work productivity and activity impairment index).
Work productivity as evaluated by the WPAI (work productivity and activity impairment index).
Time frame: between baseline and week 112
Pharmaco-economic evaluation
Pharmaco-economic evaluation of drug cost, hospitalization, work absenteeism, surgery collected and documented during the study
Time frame: between baseline and week 112
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in May 2026, 56 months.
Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 69. This study's 56 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2026 → May 2026 and completion Jun 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ustekinumab
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW